代谢组学是继基因组学、蛋白质组学、转录组学后出现的新兴“组学”，常用于疾病诊断、医药研制开发、营养食品科学、 毒理学、环境学、植物学等与人类健康密切相关的领域。自20世纪以来，每年发表的代谢组学研究的文章数量不断增加，特别是 代谢组学在肿瘤方面的研究亦在不断增多。从表面上看代谢组学的发展很迅速，但是仍然远远落后于基因组学和蛋白质组学。 代谢组学的出现是生命科学研究的必然，是对某一生物或细胞中小分子代谢产物进行定性和定量分析的一门新学科。肿瘤是严 重危害人类健康与生命的常见疾病，而且肿瘤均存在细胞代谢改变的特征，因此，代谢组学在肿瘤代谢标志物的筛选、预后的评 定、药物靶点的设计等方面可显示出巨大的潜力。代谢组学目前已经被广泛应用在多种肿瘤的研究中，而且随着代谢组学分析 平台、生物信息学技术的不断进步及数据库的建立，其将会在肿瘤的临床诊断及治疗中发挥非常重要的作用。本文就代谢组学 及其在肿瘤中的研究进展进行综述。

Metabolomics is an emerging "omics" after genomics, proteomics and transcriptomics, which is often used in disease diagnosis, medical research and development, nutrition and food science, toxicology, environmental science, botany and other fields closely related to human health. Since the 20th century, the number of articles on metabonomics published every year has been increasing. In particular, the research of metabonomics in tumor is also increasing. On the surface, metabonomics is developing rapidly, but it still lags far behind genomics and proteomics. The emergence of metabonomics is the necessity of life science research. Metabonomics is a new subject for qualitative and quantitative analysis of small molecular metabolites in a certain organism or cell. Tumor is a common disease that seriously endangers human health and life, and all tumors are characterized by changes in cell metabolism. Therefore, metabolomics shows great potential in the screening of tumor metabolic markers, the evaluation of prognosis, and the design of drug targets.At present, metabonomics has been widely used in the study of various tumors, and with the continuous progress of metabonomics analysis platform, bioinformatics technology and the establishment of database, it will play a very important role in the clinical diagnosis and treatment of tumors. In this review, metabolomics and its research progress in tumor are reviewed.